Gelteq Limited Ordinary Shares (GELS) 10-Year Financial Performance & Capital Metrics

GELS • • Industrial / General

HealthcareSpecialty & Generic PharmaMedical Devices & Drug DeliveryDrug Delivery Systems

AboutGelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals. It offers white label gel-based delivery solutions for prescription drugs, over-the-counter products, nutraceuticals and sports, pet care, and other products. The company was incorporated in 2017 and is headquartered in Caulfield, Australia.Show more

Revenue $0 -100.0%
EBITDA -$2M +7.5%
Net Income -$4M -1.1%
EPS (Diluted) 0.00 +100.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -21% -18.3%
ROIC -11.14% -2.8%
Debt/Equity 0.25 +90.7%
Interest Coverage -5.03 +34.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 100.0% through buybacks

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-

EPS CAGR

10Y-

5Y-

3Y-

TTM-

ROCE

10Y Avg-12.22%

5Y Avg-12.22%

3Y Avg-14.52%

Latest-15.5%

Peer Comparison

Drug Delivery Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
EMBCEmbecta Corp.	746.07M	12.60	7.78	-3.8%	8.77%		24.45%
SNOASonoma Pharmaceuticals, Inc.	5.56M	3.27	-1.17	12.19%	-20.54%	-91.87%		0.07
GELSGelteq Limited Ordinary Shares	13.28M	1.24		-100%	-27.42%	-26.77%		0.25

Profit & Loss

	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024
Sales/Revenue+	0	0	147.54K	79.84K	0
Revenue Growth %	-	-	-	-0.46%	-1%
Cost of Goods Sold+	0	0	94.87K	48.92K	0
COGS % of Revenue	-	-	0.64%	0.61%	-
Gross Profit+	0	0	52.66K	30.92K	0
Gross Margin %	-	-	0.36%	0.39%	-
Gross Profit Growth %	-	-	-	-0.41%	-1%
Operating Expenses+	529.62K	647.62K	3.25M	3.13M	2.95M
OpEx % of Revenue	-	-	22%	39.24%	-
Selling, General & Admin	230.52K	463.73K	1.55M	1.7M	1.27M
SG&A % of Revenue	-	-	10.48%	21.26%	-
Research & Development	342.36K	277.06K	529.02K	665.03K	276.06K
R&D % of Revenue	-	-	3.59%	8.33%	-
Other Operating Expenses	-43.26K	-93.16K	1.17M	770.18K	1.4M
Operating Income+	0	-647.62K	-3.19M	-3.1M	-2.95M
Operating Margin %	-	-	-21.64%	-38.85%	-
Operating Income Growth %	-	-	-3.93%	0.03%	0.05%
EBITDA+	-527.23K	-589.68K	-1.98M	-1.88M	-1.73M
EBITDA Margin %	-	-	-13.41%	-23.49%	-
EBITDA Growth %	-	-0.12%	-2.35%	0.05%	0.08%
D&A (Non-Cash Add-back)	2.39K	57.95K	1.22M	1.23M	1.21M
EBIT	-529.62K	-647.62K	-3.19M	-3.1M	-2.96M
Net Interest Income+	0	-1.3K	-175.63K	-404.07K	-600.22K
Interest Income	0	0	0	0	0
Interest Expense	0	1.3K	174.5K	403.52K	585.12K
Other Income/Expense	-529.62K	-1.3K	-175.63K	-404.07K	-600.22K
Pretax Income+	-529.62K	-648.92K	-3.37M	-3.51M	-3.55M
Pretax Margin %	-	-	-22.83%	-43.91%	-
Income Tax+	-154.03K	0	0	0	0
Effective Tax Rate %	0.71%	1%	1%	1%	1%
Net Income+	-375.59K	-648.92K	-3.37M	-3.51M	-3.55M
Net Margin %	-	-	-22.83%	-43.91%	-
Net Income Growth %	-	-0.73%	-4.19%	-0.04%	-0.01%
Net Income (Continuing)	-375.59K	-648.92K	-3.37M	-3.51M	-3.55M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.16	-0.07	-0.36	-0.37	0.00
EPS Growth %	-	0.57%	-4.23%	-0.03%	1%
EPS (Basic)	-0.16	-0.07	-0.36	-0.37	0.00
Diluted Shares Outstanding	2.35M	9.44M	9.44M	9.44M	0
Basic Shares Outstanding	2.35M	9.44M	9.44M	9.44M	0
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024
Total Current Assets+	574.5K	374.91K	720.07K	990.97K	303.23K
Cash & Short-Term Investments	319.52K	181.66K	162.49K	399.22K	24.52K
Cash Only	319.52K	181.66K	162.49K	399.22K	24.52K
Short-Term Investments	0	0	0	0	0
Accounts Receivable	254.98K	193.25K	250.67K	345.29K	183K
Days Sales Outstanding	-	-	620.14	1.58K	-
Inventory	0	0	95.2K	95.2K	0
Days Inventory Outstanding	-	-	366.26	710.24	-
Other Current Assets	0	0	98.75K	3.79K	16.07K
Total Non-Current Assets+	44.62K	23.84M	22.69M	21.5M	20.45M
Property, Plant & Equipment	0	0	40K	10K	16.64K
Fixed Asset Turnover	-	-	3.69x	7.98x	-
Goodwill	0	0	0	0	0
Intangible Assets	44.62K	23.84M	22.65M	21.49M	20.44M
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0
Total Assets+	619.12K	24.22M	23.41M	22.49M	20.76M
Asset Turnover	-	-	0.01x	0.00x	-
Asset Growth %	-	38.12%	-0.03%	-0.04%	-0.08%
Total Current Liabilities+	229.94K	235.9K	1.08M	1.36M	3.87M
Accounts Payable	170.34K	85.13K	216.72K	291.27K	387.03K
Days Payables Outstanding	-	-	833.79	2.17K	-
Short-Term Debt	4.59K	4.8K	5.09K	5.09K	2.08M
Deferred Revenue (Current)	0	0	119.77K	85.36K	125.36K
Other Current Liabilities	0	6.94K	39.52K	77.78K	98.37K
Current Ratio	2.50x	1.59x	0.67x	0.73x	0.08x
Quick Ratio	2.50x	1.59x	0.58x	0.66x	0.08x
Cash Conversion Cycle	-	-	152.61	115.74	-
Total Non-Current Liabilities+	166.11K	167.33K	1.47M	2.47M	1.78M
Long-Term Debt	166.11K	167.33K	1.46M	2.47M	1.76M
Capital Lease Obligations	0	0	11.9K	0	0
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	20.02K
Total Liabilities	396.04K	403.23K	2.55M	3.84M	5.65M
Total Debt+	170.7K	172.12K	1.51M	2.49M	3.84M
Net Debt	-148.82K	-9.54K	1.35M	2.09M	3.82M
Debt / Equity	0.77x	0.01x	0.07x	0.13x	0.25x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-499.32x	-18.30x	-7.69x	-5.03x
Total Equity+	223.07K	23.82M	20.86M	18.66M	15.11M
Equity Growth %	-	105.76%	-0.12%	-0.11%	-0.19%
Book Value per Share	0.10	2.52	2.21	1.98	-
Total Shareholders' Equity	223.07K	23.82M	20.86M	18.66M	15.11M
Common Stock	300.23K	24.93M	25.3M	26.61M	26.61M
Retained Earnings	-460.43K	-1.11M	-4.48M	-7.95M	-11.5M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	34.72K	0	0
Minority Interest	0	0	0	0	0

Cash Flow

	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024
Cash from Operations+	0	0	0	-1.77M	-1.07M
Operating CF Margin %	-	-	-	-22.17%	-
Operating CF Growth %	-	-	-	-	0.4%
Net Income	0	0	0	-3.51M	-3.55M
Depreciation & Amortization	0	0	0	0	0
Stock-Based Compensation	0	0	0	0	0
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	0	0	0	1.74M	2.48M
Working Capital Changes	0	0	0	0	0
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	0	0	0	0	0
Cash from Investing+	-10K	138.89K	0	-75.93K	-148.17K
Capital Expenditures	0	0	0	-34.5K	-3.15K
CapEx % of Revenue	-	-	-	0.43%	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	-10K	0	0	-41.43K	-145.02K
Cash from Financing+	681.55K	200	1.49M	2.03M	843.94K
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	323.64K	0	0	-121.84K	0
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-354.11K	-276.95K	-1.51M	-1.85M	-1.22M
FCF Margin %	-	-	-10.22%	-23.12%	-
FCF Growth %	-	0.22%	-4.44%	-0.22%	0.34%
FCF per Share	-0.15	-0.03	-0.16	-0.20	-
FCF Conversion (FCF/Net Income)	-	-	-	0.50x	0.30x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-168.37%	-5.4%	-15.08%	-17.75%	-21%
Return on Invested Capital (ROIC)	-	-4.07%	-10.41%	-10.83%	-11.14%
Gross Margin	-	-	35.69%	38.72%	-
Net Margin	-	-	-2283.44%	-4391.39%	-
Debt / Equity	0.77x	0.01x	0.07x	0.13x	0.25x
Interest Coverage	-	-499.32x	-18.30x	-7.69x	-5.03x
FCF Conversion	-	-	-	0.50x	0.30x
Revenue Growth	-	-	-	-45.88%	-100%

Frequently Asked Questions

Growth & Financials

Gelteq Limited Ordinary Shares (GELS) reported $0.1M in revenue for fiscal year 2024.

Gelteq Limited Ordinary Shares (GELS) saw revenue decline by 100.0% over the past year.

Gelteq Limited Ordinary Shares (GELS) reported a net loss of $4.0M for fiscal year 2024.

Dividend & Returns

Gelteq Limited Ordinary Shares (GELS) has a return on equity (ROE) of -21.0%. Negative ROE indicates the company is unprofitable.

Gelteq Limited Ordinary Shares (GELS) had negative free cash flow of $1.8M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener